TransCode Therapeutics Inc chart

Last update: 2022-12-30
Key statistics and financials
Revenue per share N/A
Dividend & YieldN/A$ (N/A)
Beta N/A
Market capitalization 5.57M
Operating cash flow -13.34M
ESG Scores unknown

Company description

TransCode Therapeutics, Inc., a biopharmaceutical company, engages in the development and commercialization of drugs and diagnostics for treating and identifying metastatic disease. Its lead therapeutic candidate, TTX-MC138, is a preclinical stage product for the treatment of metastatic cancer. The company's products in preclinical programs include TTX-siPDL1, an siRNA-based modulator of programmed death-ligand 1; TTX-siLIN28B, an siRNA-based inhibitor of RNA-binding protein LIN28B. Its cancer agnostic programs comprise TTX-RIGA, an RNA–based agonist of the RIG-I-driven immune response in the tumor microenvironment; TTX-CRISPR, a CRISPR/Cas9–based therapy platform for the repair or elimination of cancer-causing genes inside tumor cells; and TTX-mRNA, an mRNA-based platform for the development of cancer vaccines meant to activate cytotoxic immune responses against tumor cells. The company was incorporated in 2016 and is based in Boston, Massachusetts.

Sector: Healthcare - Industry: Biotechnology

Financial data

Financial Statements

Cashflow Statement 2018-12-31 2019-12-31 2020-12-31 2021-12-31
Change To Liabilities 58.66k -54.74k 191.25k 2.32M
Total Cashflows From Investing Activities -251.82k -251.82k -251.82k -251.82k
Net Borrowings 547.16k 500k 1.19M
Total Cash From Financing Activities 512.43k 500k 1.12M 25.52M
Change To Operating Activities 24.94k 50.04k 118.51k -1.85M
Issuance Of Stock 3.42k 26.38M 26.38M 26.38M
Net Income -453.44k -607.21k -2.34M -6.84M
Change In Cash 212.86k -8.51k 623.54k 20M
Effect Of Exchange Rate
Total Cash From Operating Activities -299.57k -508.51k -492.97k -5.27M
Depreciation 42.47k 42.47k 42.47k 42.47k
Change To Account Receivables
Other Cashflows From Financing Activities -38.15k -73.48k -73.48k -860.94k
Change To Netincome 70.27k 103.41k 1.54M 1.07M
Capital Expenditures -254.82k -254.82k -254.82k -254.82k

Income Statement 2018-12-31 2019-12-31 2020-12-31 2021-12-31
Research Development 82.53k 226.31k 284.46k 2.75M
Income Before Tax -453.44k -607.21k -2.34M -6.84M
Net Income -453.44k -607.21k -2.34M -6.84M
Selling General Administrative 301.46k 230.56k 442.14k 3.4M
Gross Profit
Ebit -384k -456.87k -726.6k -6.15M
Operating Income -384k -456.87k -726.6k -6.15M
Interest Expense -68.97k -156.97k -394.57k -95.07k
Income Tax Expense
Total Revenue
Cost Of Revenue
Total Other Income ExpenseNet -69.44k -150.35k -1.62M -692.26k
Net Income From Continuing Ops -453.44k -607.21k -2.34M -6.84M
Net Income Applicable To Common Shares -453.44k -607.21k -2.34M -6.84M

Balance Sheet Statement 2018-12-31 2019-12-31 2020-12-31 2021-12-31
Total Liabilities 718.61k 1.31M 4.46M 2.53M
Total Stockholder Equity -503.97k -1.11M -3.41M 20.4M
Other Current Liabilities 30.53k
Total Assets 214.65k 204.47k 1.06M 22.94M
Common Stock 764 464 464 1.29k
Other Current Assets 441.59k
Retained Earnings -510.78k -1.12M -3.46M -10.31M
Treasury Stock -11.8k -12.27k -12.76k
Cash 212.98k 204.47k 828.02k 20.83M
Total Current Liabilities 117.68k 62.94k 404.86k 2.53M
Other Stockholder Equity -11.8k -12.27k -12.76k
Property, Plant, and Equipment 206.27k
Total Current Assets 214.65k 204.47k 831.22k 22.73M
Net Tangible Assets -503.97k -1.11M -3.41M 20.4M
Net Receivables
Accounts Payable


Insider Transactions

Here are the insider transactions of stock shares related to TransCode Therapeutics Inc:

Filer Name Transaction Text Ownership Date Filer Relation Shares
DUDLEY ROBERT MICHAELPurchase at price 1.15 per share.D2022-09-14Chief Executive Officer20k
FITZGERALD THOMAS APurchase at price 1.27 per share.D2022-06-16Chief Financial Officer12k
DUDLEY ROBERT MICHAELPurchase at price 1.84 - 1.87 per share.D2022-05-31Chief Executive Officer30k

Insider transaction explanations

Insider buying is the legal purchase of shares by a senior executive or director of a company. "Filer Name" corresponds to the name of the stock buyer or seller. "Transaction Text" describes the transaction. "Ownership" gives information about the transaction type. "Date" is the reported transaction date. "Filer Relation" gives the role of the insider in the company. "Shares" is the value of the transaction. You will find the complete description of the General Transaction Codes on the SEC dedicated page


Investment strategy backtesting

These are the result of three automatic investment systems applied to TransCode Therapeutics Inc. You will find the performance of an systematic investment system, a momentum strategy, and a buy the dip trading strategy.


Systematic investment results on TransCode Therapeutics Inc

Here is the result of two systematic investment strategies applied to TransCode Therapeutics Inc. The first strategy automatically buys the first day of the month, and the second strategy buys the fifteenth day of the month.

Systematic investment equity curve on TransCode Therapeutics Inc

The following chart shows the equity curve of the two systematic investment strategies applied to TransCode Therapeutics Inc:

TransCode Therapeutics Inc automated entries

The systematic investment strategy that buys the first day of the month would give a performance of 0% on the backtest period.

Performance at glance

Performance

0 %

Latent gain

0.0 $

Invested capital

0.0 $

Annualized return

0.0 %
Build your Trading System
Automated Trading using Prorealtime ebook

Momentum strategy results on TransCode Therapeutics Inc

This is the result of two momentum investment strategies applied to TransCode Therapeutics Inc. The first strategy uses a momentum signal calculated on one quarter, and the second uses a momentum signal calculated on two quarters.

Momentum entry openings on TransCode Therapeutics Inc

The following chart shows all the entries opened by the momentum investment system on TransCode Therapeutics Inc:

TransCode Therapeutics Inc momentum entries
  • The first momentum investment strategy would give 0% of return on TransCode Therapeutics Inc. That represents 0.0$ of latent gain with 0.0$ of employed capital.
  • The second momentum investment strategy would give 0% of return on TransCode Therapeutics Inc. That represents 0.0$ of latent gain with 0.0$ of employed capital.
Performance at glance (1Q Momentum)

Performance

0 %

Latent gain

0.0 $

Invested capital

0.0 $

Annualized return

-0.0 %
Performance at glance (2Q Momentum)

Performance

0 %

Latent gain

0.0 $

Invested capital

0.0 $

Annualized return

-0.0 %

Momentum equity curve on TransCode Therapeutics Inc

The following chart shows the equity curve of the two momentum strategies applied to TransCode Therapeutics Inc:

TransCode Therapeutics Inc momentum equity

Note: the dividends potentially given by TransCode Therapeutics Inc are not integrated into the calculation of the equity curve neither the performance of the strategy. The integration of the dividends will be available soon.


Employed capital on TransCode Therapeutics Inc

The following chart shows the employed capital evolution of the two momentum strategies on TransCode Therapeutics Inc since the beginning:

TransCode Therapeutics Inc

Note: the algorithm buys for a maximum of 250$ per entry. If the stock price is greater than 250$, the system buys only one stock per entry. The investment system stops automatically when the financial exposure reaches 10000$.


Buy the dip strategy result on TransCode Therapeutics Inc

Buy the dip entry openings on TransCode Therapeutics Inc

TransCode Therapeutics Inc

The performance achieved by the robo-advisor on TransCode Therapeutics Inc is 0%. That represents 0.0$ of latent gain with 0.0$ of employed capital. The following chart shows TransCode Therapeutics Inc stock price with all the entries opened by the automated investment system.

Note: The blue line represents the weekly stock price of TransCode Therapeutics Inc, and the green triangles represent the entry openings. The artificall robo-advisor needs at least 100 weeks of trading history to work.

Performance at glance

Performance

0 %

Latent gain

0.0 $

Invested capital

0.0 $

Annualized return

-0.0 %

Equity curve of the strategy applied to TransCode Therapeutics Inc

The following chart shows the result of the investment strategy applied to TransCode Therapeutics Inc:

TransCode Therapeutics Inc

Note: the dividends potentially given by TransCode Therapeutics Inc are not integrated into the calculation of the equity curve neither the performance of the strategy. The integration of the dividends will be available soon.


Employed capital on TransCode Therapeutics Inc

The following chart shows the employed capital evolution since the beginning of the investment strategy on TransCode Therapeutics Inc:

TransCode Therapeutics Inc

Note: the algorithm buys for a maximum of 250$ per entry. If the stock price is greater than 250$, the system buys only one stock per entry. The investment system stops automatically when the financial exposure reaches 10000$.


Investment strategies comparison on TransCode Therapeutics Inc

In this section, I will compare the three previous investment strategies applied to TransCode Therapeutics Inc.

Equity curve comparison on TransCode Therapeutics Inc

The following chart shows the equity curve of the artificall advisor, the trend folowing and the automatic investment strategies:

TransCode Therapeutics Inc investment strategy comparison

Employed capital comparison on TransCode Therapeutics Inc

TransCode Therapeutics Inc investment comparison

Performance comparison on TransCode Therapeutics Inc

Strategy Latent Profit Growth Employed capital CAGR
Automatic investment 0% 0.0$ 0.0$ 0.0%
Momentum 1 quarter 0% 0.0$ 0.0$ -0.0%
Momentum 2 quarters 0% 0.0$ 0.0$ -0.0%
Non-directional 0% 0.0$ 0.0$ -0.0%
Annualized return comparison

Automatic investment

0.0 %

Momentum 1Q

-0.0 %

Momentum 2Q

-0.0 %

Non-directional

-0.0 %

Correlated stocks

Here are the most positively and negatively correlated stocks with TransCode Therapeutics Inc:

Positive correlations

Most correlated stocks this year


Most correlated stocks last 3 months

Negative correlation

Most negatively correlated stocks this year


Most negatively correlated stocks last 3 months

Note: The algorithm computes the probability of correlation between TransCode Therapeutics Inc and the other stocks. There may be false positives or some missing correlated stocks. If the price of TransCode Therapeutics Inc does not vary for 36 weeks, the correlation calculation result will be wrong.


Company information

Company name TransCode Therapeutics Inc
Country United States
City Boston
Address 6 Liberty Square
Phone 857-837-3099
Website www.transcodetherapeutics.com
FullTime employees 8
Industry Biotechnology
Sector Healthcare
Exchange XNAS
Ticker RNAZ
Market www.nasdaq.com

TransCode Therapeutics Inc ESG Scores

Environment scores

Environment ESG Factors Scores
Environment Score 0
Peer Environment Performance unknown
Environment Percentile unknown
Palm Oil unknown
Nuclear unknown
Fur Leather unknown
GMO unknown
Coal unknown
Pesticides unknown
Animal Testing unknown

Social scores

Social ESG Factors Scores
Social Score 0
Peer Social Performance unknown
Social Percentile unknown
Highest Controversy unknown
Peer Highest Controversy Performance unknown
Adult unknown
Gambling unknown
Alcoholic unknown
Tobacco unknown
Catholic unknown
Controversial Weapons unknown
Small Arms unknown
Military Contract unknown
Peer Count unknown

Related Controversy:


Governance scores

Governance ESG Factors Scores
Governance Score 0
Peer Governance Performance unknown
Governance Percentile unknown

ESG at glance
Total ESG Scores: unknown
Environment Score: 0
Social Score: 0
Governance Score: 0

ESG Performance: unknown

Peer Group: unknown

Peer Esg Score Performance: unknown

Rating Year: unknown

Rating Month: unknown

Max Age: unknown

Percentile: unknown